Aclaris Therapeutics, Inc. Quarterly Cost of Revenue in USD from Q3 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Aclaris Therapeutics, Inc. quarterly/annual Cost of Revenue history and growth rate from Q3 2017 to Q3 2024.
  • Aclaris Therapeutics, Inc. Cost of Revenue for the quarter ending September 30, 2024 was $654K, a 22.9% decline year-over-year.
  • Aclaris Therapeutics, Inc. Cost of Revenue for the twelve months ending September 30, 2024 was $2.81M, a 21.3% decline year-over-year.
  • Aclaris Therapeutics, Inc. annual Cost of Revenue for 2023 was $3.42M, a 14.9% decline from 2022.
  • Aclaris Therapeutics, Inc. annual Cost of Revenue for 2022 was $4.02M, a 14.6% decline from 2021.
  • Aclaris Therapeutics, Inc. annual Cost of Revenue for 2021 was $4.71M, a 8.18% decline from 2020.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $2.81M $654K -$194K -22.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $3.01M $624K -$418K -40.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $3.42M $809K +$1K +0.12% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $3.42M $725K -$152K -17.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $3.58M $848K -$75K -8.13% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $3.65M $1.04M -$26K -2.43% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $3.68M $808K -$347K -30% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $4.02M $877K -$272K -23.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $4.3M $923K -$176K -16% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $4.47M $1.07M -$195K -15.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $4.67M $1.16M -$47K -3.91% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $4.71M $1.15M -$137K -10.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $4.85M $1.1M -$90K -7.57% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $4.94M $1.26M -$126K -9.07% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $5.07M $1.2M -$67K -5.28% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $5.13M $1.29M +$258K +25.1% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 $4.88M $1.19M +$363K +43.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 $4.51M $1.39M +$395K +39.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $4.12M $1.27M +$62K +5.14% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $4.06M $1.03M -$86K -7.72% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $4.14M $826K -$241K -22.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $4.38M $994K -$187K -15.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $4.57M $1.21M +$240K +24.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $4.33M $1.11M Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $1.07M +$614K +136% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $1.18M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $967K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q3 2017 $453K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.